Alkermes (ALKS) Income from Continuing Operations (2010 - 2026)
Alkermes' (ALKS) quarterly Income from Continuing Operations came in at 66526000.0 in Q1 2026, down 395.82% year-on-year from 22489000.0 in Q1 2025, and down 168.87% on a QoQ basis from 96601000.0 in Q4 2025.
Alkermes (ALKS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Income from Continuing Operations data on file, last reported at 66526000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 395.82% year-over-year to 66526000.0 in Q1 2026; TTM through Mar 2026 was 199918000.0, a 53.29% decrease from a year earlier, with the FY2025 full-year figure at 288924000.0, down 34.99% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 66526000.0, down from 96601000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ALKS reached as high as 279129000.0 in Q2 2023 and fell as low as 66526000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 67277411.76 across 5 years, with a median of 87098000.0 in 2025.
- Across the five-year window, Income from Continuing Operations tumbled 1374.79% in 2022 and surged 1026.23% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 87716000.0 in 2022, then surged by 83.04% to 160554000.0 in 2023, then surged by 35.81% to 218049000.0 in 2024, then sank by 55.7% to 96601000.0 in 2025, then slumped by 168.87% to 66526000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 66526000.0 in Q1 2026, 96601000.0 in Q4 2025, and 82745000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -66.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.53 Mn |
| Dec 31, 2025 | 96.60 Mn |
| Sep 30, 2025 | 82.75 Mn |
| Jun 30, 2025 | 87.10 Mn |
| Mar 31, 2025 | 22.49 Mn |
| Dec 31, 2024 | 218.05 Mn |
| Sep 30, 2024 | 92.83 Mn |
| Jun 30, 2024 | 94.66 Mn |
| Mar 31, 2024 | 38.91 Mn |
| Dec 31, 2023 | 160.55 Mn |
| Sep 30, 2023 | 91.51 Mn |
| Jun 30, 2023 | 279.13 Mn |
| Mar 31, 2023 | -12.03 Mn |
| Dec 31, 2022 | 87.72 Mn |
| Sep 30, 2022 | -63.97 Mn |
| Jun 30, 2022 | -30.14 Mn |
| Mar 31, 2022 | -35.90 Mn |
| Dec 31, 2021 | 137.03 Mn |
| Sep 30, 2021 | -28.99 Mn |
| Jun 30, 2021 | 2.36 Mn |